

Errata

Diakos et al. RNAi-mediated silencing of *TEL/AML1* reveals a heat-shock protein- and survivin-dependent mechanism for survival. *Blood*. 2007;109:2607-2610.

On page 2607 in the March 15, 2007, issue, the last author's last name is misspelled. The correct name is E. Renate Panzer-Grümayer. The error was corrected in the online version, which now differs from the print version.

Luciano et al. Nur77 converts phenotype of Bcl-B, an antiapoptotic protein expressed in plasma cells and myeloma. *Blood*. 2007;109:3849-3855.

In the online data supplement and on page 3852 in the May 1, 2007, issue, there were errors in several figures.

In online Figures S1 and S7, the authors spliced lanes without indicating that they had done so. Figures S1 and S7 and the figure legends were corrected in the online version. The corrected supplemental figures now show with vertical lines the positions at which extraneous lanes from the blot were digitally excised.

Figure 2 contains lane duplications in the Bcl-2 Western blot. The entire experiment was repeated because the primary data from this experiment were not sufficiently documented to allow reconstruction of the figure. The corrected Figure 2 and figure legend are shown.




Figure 2. Nur77 collaborates with Bcl-2, Bfl-1, and Bcl-B to induce apoptosis. HeLa cells in 12-well plates were cotransfected with 0.3 μ g plasmids encoding either GFP or GFP-Nur77 Δ DBD in combination with 1 μ g plasmids encoding the 6 antiapoptotic Bcl-2 family members. After 1 day, cells were washed with PBS, fixed with 3.7% formaldehyde, and stained with DAPI to visualize nuclei by UV microscopy. The percentages of apoptotic cells were determined by counting 200 GFP-positive cells, scoring cells having nuclear fragmentation and/or chromatin condensation. Data are reported as means plus or minus SE (n = 3). For assessing protein expression (bottom 3 panels), lysates were prepared from transfected cells, normalized for total protein content, and analyzed by SDS-PAGE/immunoblotting using Bcl-2, Myc, and GFP antibodies. The Bcl-2 data were derived from a single blot, and the bands were aligned with the apoptosis results for clarity of presentation.

Khouri et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. *Blood*. 2008;111:5530-5536.

On page 5533 of the June 15, 2008, issue, there is an error in reporting the confidence intervals related to the 11% incidence of acute 2-IV graft-versus-host disease. The first sentence of the

second paragraph under the heading "Survival and toxicity" should have read: "The incidence of grade 2-IV acute GVHD was 11% (95% CI, 5%-24%; Figure 4)."